Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol-Glycopyrronium in Idiopathic Bronchiectasis With Airflow Limitation
NCT04509661Phase 4Unknown
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Sep 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of indacaterol and glycopyrrolate metered dose inhaler in bronchiectasis (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Acute exacerbation at 1 year. Status: unknown.
02
Drugs
indacaterolglycopyrrolate metered dose inhaler
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT04509661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04509661.